| Question 1: Question 1:
For MRI-based GYN HDR brachytherapy, MRI sequence used in the planning is |
| Reference: | 1. Dimopoulos JC, Petrow P, Tanderup K, et al. Recommendations from Gynaecological (GYN) GEC‐ESTRO Working Group (IV): Basic principles and parameters for MR imaging within the frame of image based adaptive cervix cancer brachytherapy. Radiother Oncol. 2012;103:113–122. |
| Choice A: | a. T1 |
| Choice B: | b. contrast enhanced T1 |
| Choice C: | c. T2 |
| Choice D: | d. contrast enhanced T2 |
| Question 2: Titanium needles cannot be used in MRI-IBT for which of the following reasons"? |
| Reference: | 1. Blumenfeld P, Hata N, DiMaio S, et al: Transperineal prostate biopsy under magnetic resonance image guidance: a needle placement accuracy study. J Magn Reson Imaging 26:688-94, 2007
2. Ladd ME, Erhart P, Debatin JF, et al: Biopsy needle susceptibility artifacts. Magn Reson Med 36:646-51, 1996 |
| Choice A: | Too thick in diameter. |
| Choice B: | Not MRI compatible. |
| Choice C: | Too expensive. |
| Choice D: | No longer available in US. |
| Question 3: 3. For a given course of treatment, if a fraction is imported in one format (eg. from an ARIA database) and then a subsequent fraction is imported in a different format (e.g., DICOM), Aria will ensure that the number of fractions delivered matches the number of fractions in the treatment plan. |
| Reference: | Reference: BRAVOS Instructions for Use 1.1MR2 EN. |
| Choice A: | a. True |
| Choice B: | b. False |
| Question 4: 4. For courses of treatment, an external beam treatment plan of TrueBeam and a Brachytherpy plan of Braovos can be opened at the same time for the same patient. |
| Reference: | Reference: BRAVOS Instructions for Use 1.1MR2 EN. |
| Choice A: | a. True |
| Choice B: | b. False |
| Question 5: Question 5
Failure mode severity in HDR 192Ir brachytherapy may be scored using the following scale: |
| Reference: | Mayadev et al. A failure modes and effects analysis study for gynecologic high-dose-rate brachytherapy. Brachytherapy 2015;14:866-875. |
| Choice A: | Pain |
| Choice B: | Richter |
| Choice C: | C-weighted decibel |
| Choice D: | Dosimetric |
| Choice E: | Enhanced Fujita |
| Question 6: Question 6
The calibration uncertainty (k=1) for HDR 192Ir source strength as measured by the medical physicist with an ADCL-traceably calibrated reentrant well-type air ionization chamber is: |
| Reference: | DeWerd et al. Uncertainties in photon brachytherapy dosimetry. A dosimetric uncertainty analysis for photon-emitting brachytherapy sources: Report of AAPM Task Group No. 138 and GEC-ESTRO. Med Phys 2011;38:782-801.
Kirisits et al. Review of clinical brachytherapy uncertainties: Analysis guidelines of GEC-ESTRO and the AAPM. Radiotherapy Oncol 2014;110:199-212. |
| Choice A: | a. 0.5% |
| Choice B: | b. 1.5% |
| Choice C: | c. 3.0% |
| Choice D: | d. 5.0% |
